Evolus, Inc.

NASDAQ:EOLS

Drug Manufacturers - Specialty & Generic

Healthcare
$7.07 -2.00%

-$0.14 today

Market cap
$467.95M
Beta
1.33
P/E (TTM)
-9.9
EPS (TTM)
-$0.67
52W Low $3.86High $10.20

Volume 0.80M

Average 0.86M

EOLS Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Evolus, Inc.NASDAQ: EOLS

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $10.67M (cash outflow) fell 43.5% year over year, behind the -22.7% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -11.5% a year.

Context

  • Net income amounted to 17.4% of revenue in FY2025, down 1.6 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$2.08M (-96.0%) for the fiscal year ending Dec 2026, a slowdown from the +2.4% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.67M-8310.8% QoQ
Last fiscal yearDec 2025
-$51.64M+2.4% YoY
LTMMar 2026
-$43.42M-22.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-43.5%-87.1%-43.6 pp
1 year+2.4%-96.0%-98.4 pp
3-year CAGR-11.5%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(51.64M) USD
Year-over-year change
-2.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How EOLS compares with its peers on the latest reported figures

No competitor Net Income figures are available to compare.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(46.81M)(74.41M)(61.69M)(50.42M)(51.64M)
Depreciation & Amortization6.31M4.5M5.87M6.02M8.74M
Deferred Income Tax15K(18K)5K(21K)21K
Stock-Based Compensation9.58M10.83M16.46M22.25M20.7M
Change in Working Capital(11.54M)(34.25M)(5.9M)(6.6M)(22.48M)
Accounts Receivables(5.57M)(9.39M)(9.52M)(19.6M)(11.51M)
Inventory(2.98M)(10.69M)4.19M3.25M(11.12M)
Accounts Payables(787K)968K(1.02M)391K10.1M
Other Working Capital(2.21M)(15.14M)450K9.36M(9.95M)
Other Non-Cash Items9.06M8.44M11.24M10.77M2.39M
Operating Cash Flow(33.39M)(84.91M)(34.01M)(18M)(42.27M)
Capital Expenditures(970K)(2.94M)(1.63M)(1.47M)(3.44M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments5M0000
Other Investing Activities(577K)(1.32M)(1.15M)(3.35M)0
Investing Cash Flow4.03M(2.94M)(1.63M)(4.82M)(8.45M)
Debt Repayment(24.37M)050M0(15K)
Common Stock Issued103.34M0051.21M1.16M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(5.92M)(4.15M)(5.36M)(3.8M)16.19M
Financing Cash Flow73.05M(4.15M)44.64M47.41M17.34M
Effect of Forex Changes(1)(337K)(90K)(478K)254K
Net Change in Cash43.69M(92.33M)8.92M24.11M(33.13M)
Free Cash Flow(34.36M)(87.85M)(35.64M)(19.47M)(45.71M)

Evolus, Inc.

NASDAQ:EOLS

Intrinsic Alpha fair value

Locked

Current Price

$7.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.